Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore

NCT07176130 | Active Not Recruiting DMC

• 1 other identifier: 2019/2811
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

This is a retrospective study analyzing demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases that presented to the Singapore National Eye Centre (SNEC).

Conditions

Uveitis; Scleritis and Episcleritis; Endophthalmitis; Masquerade Syndromes; Intraocular Lymphoma

Keywords

Uveitis; Scleritis; Masquerades syndromes; Intraocular lymphoma; Endophthalmitis

Outcome Measures

Primary Outcomes (1)

• Distribution of demographics, diagnosis, clinical features, treatment and outcomes

  Percentage ethnic distribution, percentage of gender distribution, percentage of age distribution, percentage of etiology, percentage of clinical features, percentage of investigations, percentage of diagnosis, percentage of secondary complications, percentage of treatment received, percentage of outcomes

  January 1987 and January 2025

Secondary Outcomes (1)

• Correlation of demographics, diagnosis, clinical features, and treatment outcomes

  January 1987 and January 2025

Study Arms (4)

Uveitis

Patients diagnosed with uveitis at Singapore National Eye Centre

Other: No Intervention: Observational Cohort

Scleritis and Episcleritis

Patients diagnosed with scleritis or episcleritis at Singapore National Eye Centre

Other: No Intervention: Observational Cohort

Intraocular lymphoma

Patients diagnosed with ocular neoplasms at Singapore National Eye Centre

Other: No Intervention: Observational Cohort

Endophthalmitis

Patients diagnosed with endophthalmitis at Singapore National Eye Centre

Other: No Intervention: Observational Cohort

Interventions

No Intervention: Observational Cohort OTHER

Not applicable, No intervention. Observational study.

Endophthalmitis; Intraocular lymphoma; Scleritis and Episcleritis; Uveitis

Eligibility Criteria

• Age: 21 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g., vitreoretinal and uveal lymphoma) and endophthalmitis, at the Singapore National Eye Centre.

You may qualify if:

• Patients diagnosed with uveitis
• Patients diagnosed with scleritis or episcleritis
• Patients diagnosed with ocular neoplasms e.g., vitreoretinal and uveal lymphoma
• Patients diagnosed with endophthalmitis
• Diagnosis confirmed by laboratory testing or histopathological examination
• Patients diagnosed and managed at the Singapore National Eye Centre (SNEC)

You may not qualify if:

• Patients with less than two years of clinical follow-up
• Patients with incomplete diagnostic confirmation (i.e., lacking laboratory or histopathological evidence)
• Patients diagnosed outside of Singapore National Eye Centre (SNEC)
• Cases with missing key clinical or outcome data

Sponsors & Collaborators

• Singapore National Eye Centre: lead

Study Sites (1)

Singapore National Eye Centre

Singapore, Singapore

Location

Related Publications (4)

• Siak J, Jansen A, Waduthantri S, Teoh CS, Jap A, Chee SP. The Pattern of Uveitis among Chinese, Malays, and Indians in Singapore. Ocul Immunol Inflamm. 2017;25(sup1):S81-S93. doi: 10.1080/09273948.2016.1188968. Epub 2016 Jul 15.

  PMID: 27419535 BACKGROUND

• Chee SP, Jap A. Endogenous endophthalmitis. Curr Opin Ophthalmol. 2001 Dec;12(6):464-70. doi: 10.1097/00055735-200112000-00012.

  PMID: 11734687 BACKGROUND

• International Vitreoretinal B-Cell Lymphoma Registry Investigator Group. Presentation, Diagnostic Testing and Initial Treatment of Vitreoretinal Lymphoma. Ophthalmol Retina. 2024 Jan;8(1):72-80. doi: 10.1016/j.oret.2023.08.012. Epub 2023 Aug 28.

  PMID: 37648063 BACKGROUND

• Carbonell D, Mahajan S, Chee SP, Sobolewska B, Agrawal R, Bulow T, Gupta V, Jones NP, Accorinti M, Agarwal M, Batchelor T, Biswas J, Cimino L, tenDam-van Loon NH, de-la-Torre A, Frenkel S, Pe'er J, Kramer M, Miserocchi E, Mochizuki M, Ness T, Rosenbaum JT, Sen HN, Simion M (VRL patient), Sitter H, Vasconcelos-Santos DV, Habot-Wilner Z, Coupland SE, Pulido JS, Smith J, Thorne JE, Zierhut M; Study Group for Vitreoretinal Lymphoma Diagnostics. Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma. Ocul Immunol Inflamm. 2021 Apr 3;29(3):507-520. doi: 10.1080/09273948.2021.1878233. Epub 2021 May 19.

  PMID: 34009095 BACKGROUND

MeSH Terms

Conditions

Uveitis; Scleritis; Endophthalmitis; Intraocular Lymphoma

Condition Hierarchy (Ancestors)

Uveal Diseases; Eye Diseases; Scleral Diseases; Eye Infections; Infections; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Eye Neoplasms; Neoplasms by Site; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Resident Physician

Study Record Dates

• First Submitted: August 30, 2025
• First Posted: September 16, 2025
• Study Start: August 19, 2025
• Primary Completion: September 30, 2025
• Study Completion: October 30, 2025
• Last Updated: September 16, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

SG (1)